The central domain of the 200-kDa Lassa virus L protein is a putative RNA-dependent RNA polymerase. N- and C-terminal domains may harbor enzymatic functions important for viral mRNA synthesis, including capping enzymes or cap-snatching endoribonucleases. In the present study, we have employed a large-scale mutagenesis approach to map functionally relevant residues in these regions. The main targets were acidic (Asp and Glu) and basic residues (Lys and Arg) known to form catalytic and binding sites of capping enzymes and endoribonucleases. A total of 149 different mutants were generated and tested in the Lassa virus replicon system. Nearly 25% of evolutionarily highly conserved acidic and basic side chains were dispensable for function of L protein in the replicon context. The vast majority of the remaining mutants had defects in both transcription and replication. Seven residues (Asp-89, Glu-102, Asp-119, Lys-122, Asp-129, Glu-180, and Arg-185) were selectively important for mRNA synthesis. The phenotype was particularly pronounced for Asp-89, Glu-102, and Asp-129, which were indispensable for transcription but could be replaced by a variety of amino acid residues without affecting genome replication. Bioinformatics disclosed the remote similarity of this region to type IIs endonucleases. The mutagenesis was complemented by experiments with the RNA polymerase II inhibitor alpha-amanitin, demonstrating dependence of viral transcription from the cellular mRNA pool. In conclusion, this paper describes an N-terminal region in L protein being important for mRNA, but not genome synthesis. Bioinformatics and cell biological experiments lend support to the hypothesis that this region could be part of a cap-snatching enzyme.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812395PMC
http://dx.doi.org/10.1128/JVI.01657-09DOI Listing

Publication Analysis

Top Keywords

lassa virus
12
n-terminal region
8
virus protein
8
transcription replication
8
rna polymerase
8
mrna synthesis
8
capping enzymes
8
asp-89 glu-102
8
region lassa
4
virus
4

Similar Publications

Current perspectives on vaccines and therapeutics for Lassa Fever.

Virol J

December 2024

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.

View Article and Find Full Text PDF

Systematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.

Am J Trop Med Hyg

December 2024

Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.

Article Synopsis
  • The systematic review focuses on reproductive health issues faced by female survivors of Lassa fever and Ebola virus disease.
  • Thirteen studies reviewed predominantly highlight negative outcomes related to reproductive health among EVD survivors, including menstrual irregularities and pregnancy loss, with no research identified on LF survivors.
  • The analysis indicates that about 14% of female EVD survivors experience adverse reproductive health outcomes, revealing a significant need for further research in this area.
View Article and Find Full Text PDF

U-73122, a phospholipase C inhibitor, impairs lymphocytic choriomeningitis virus virion infectivity.

J Gen Virol

December 2024

Laboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.

Lassa virus (LASV) is an Old World (OW) mammarenavirus that causes Lassa fever, a life-threatening acute febrile disease endemic in West Africa. Lymphocytic choriomeningitis virus (LCMV) is a worldwide-distributed, prototypic OW mammarenavirus of clinical significance that has been largely neglected as a human pathogen. No licensed OW mammarenavirus vaccines are available, and the current therapeutic option is limited to the off-label use of ribavirin, which offers only partial efficacy.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explores how Lassa fever develops and the factors that determine whether it results in a mild or severe illness, using a monkey model to replicate different disease outcomes.
  • - It finds that lymphoid organs are key early sites for the replication of the Lassa virus, which can enter through lymph node structures regardless of whether the infection is fatal or not.
  • - The severity of the disease correlates with how the virus spreads; in nonfatal cases, it largely stays within lymphoid tissues, while fatal outcomes see the virus invade multiple organs, triggering a strong immune inflammatory response.
View Article and Find Full Text PDF

Background: Viral hemorrhagic fevers (VHFs) belong to a group of viral infectious diseases that interfere with the blood's clotting mechanism. VHF has a wide host range, including bats, rodents, or arthropods such as mosquitoes and ticks. Most VHFs emerge suddenly as outbreaks, making it difficult to predict occurrence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!